CDK4 and meningioma: Preclinical evidence supports the use of CDK4/6 specific inhibitors, Palbociclib, Abemaciclib, and Ribociclib, as potential therapeutic agents for meningioma patients and these agents are actively being explored in ongoing clinical trials.